2015Chinese Journal of General PracticeRequires access

Clinical application of leukocyte reduction filter for platelet

Xu Xu

Open publisher page 0 citations

Abstract

Objective The platelet antibody is the immune factor causing platelet transfusion refractoriness( PTR). This study is designed to evaluate the clinical value of domestic leukocyte reduction filter for platelet by means of investigating whether these filters could reduce the probability of platelet antibodies in patients or delay the time of generating platelet antibodies. Methods Forty patients with hematological diseases were selected as non leukoreduced group,each of them recently received apheresis platelet transfusion more than 3 times,and these apheresis platelets were all not filtered with leukocyte reduction filter for platelet. Another 40 patients with hematological diseases were selected as leukoreduced group,each of them recently received apheresis platelet transfusion more than 3 times,and these apheresis platelets were all filtered with leukocyte filter for platelet. According to times of apheresis platelet transfusion,each group was divided into 5 subgroups named a,b,c,d and e. All the selected patients did not have previous history of blood transfusion. The platelet antibody screening for each patient was respectively done with solid agglutination method. The positive rates of platelet antibody of non leukoreduced group and leukoreduced group and each subgroup were respectively calculated,and the differences of positive rates between non leukoreduced group and leukoreduced group were compared by using χ2test.Results Eighteen cases of positive platelet antibody were screened out in non leukoreduced group with a positive rate of45%( 18 /40); 5 cases of positive platelet antibody were screened out in leukoreduced group with a positive rate of 12. 5%( 5 /40),the differences of positive rates between non leukoreduced group and leukoreduced group was significant( χ2=10. 31,P 0. 05). The positive rates of platelet antibody in both groups were increased with numbers of apheresis platelets transfusion times. Conclusion Apheresis platelets filtered with domestic leukocyte reduction filter for platelet can greatly reduce the probability of generating platelet antibody,and postpone the time of producing platelet antibody. Leukocyte reduction filter for platelet deserves to be spread in clinical practice.

About this research paper

What this paper is about

Objective The platelet antibody is the immune factor causing platelet transfusion refractoriness( PTR). This study is designed to evaluate the clinical value of domestic leukocyte reduction filter for platelet by means of investigating whether these filters could reduce the probability of platelet antibodies in patients or delay the time of generating platelet antibodies. Methods Forty patients with hematological diseases were selected as non leukoreduced group,each of them recently received apheresis platelet transfusion more than 3 times,and these apheresis platelets were all not filtered with leukocyte reduction filter for platelet. Another 40 patients with hematological diseases were selected as leukoreduced group,each of them recently received apheresis platelet transfusion more than 3 times,and these apheresis platelets were all filtered with leukocyte filter for platelet. According to times of apheresis platelet transfusion,each group was divided into 5 subgroups named a,b,c,d and e. All the selected patients did not have previous history of blood transfusion. The platelet antibody screening for each patient was respectively done with solid agglutination method. The positive rates of platelet antibody of non leukoreduced group and leukoreduced group and each subgroup were respectively calculated,and the differences of positive rates between non leukoreduced group and leukoreduced group were compared by using χ2test.Results Eighteen cases of positive platelet antibody were screened out in non leukoreduced group with a positive rate of45%( 18 /40); 5 cases of positive platelet antibody were screened out in leukoreduced group with a positive rate of 12. 5%( 5 /40),the differences of positive rates between non leukoreduced group and leukoreduced group was significant( χ2=10. 31,P 0. 05). The positive rates of platelet antibody in both groups were increased with numbers of apheresis platelets transfusion times. Conclusion Apheresis platelets filtered with domestic leukocyte reduction filter for platelet can greatly reduce the probability of generating platelet antibody,and postpone the time of producing platelet antibody. Leukocyte reduction filter for platelet deserves to be spread in clinical practice.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective The platelet antibody is the immune factor causing platelet transfusion refractoriness( PTR). This study is designed to evaluate the clinical value of domestic leukocyte reduction filter for platelet by means of investigating whether these filters could reduce the probability of platelet antibodies in patients or delay the time of generating platelet antibodies. Methods Forty patients with hematological diseases were selected as non leukoreduced group,each of them recently received apheresis platelet transfusion more than 3 times,and these apheresis platelets were all not filtered with leukocyte reduction filter for platelet. Another 40 patients with hematological diseases were selected as leukoreduced group,each of them recently received apheresis platelet transfusion more than 3 times,and these apheresis platelets were all filtered with leukocyte filter for platelet. According to times of apheresis platelet transfusion,each group was divided into 5 subgroups named a,b,c,d and e. All the selected patients did not have previous history of blood transfusion. The platelet antibody screening for each patient was respectively done with solid agglutination method. The positive rates of platelet antibody of non leukoreduced group and leukoreduced group and each subgroup were respectively calculated,and the differences of positive rates between non leukoreduced group and leukoreduced group were compared by using χ2test.Results Eighteen cases of positive platelet antibody were screened out in non leukoreduced group with a positive rate of45%( 18 /40); 5 cases of positive platelet antibody were screened out in leukoreduced group with a positive rate of 12. 5%( 5 /40),the differences of positive rates between non leukoreduced group and leukoreduced group was significant( χ2=10. 31,P 0. 05). The positive rates of platelet antibody in both groups were increased with numbers of apheresis platelets transfusion times. Conclusion Apheresis platelets filtered with domestic leukocyte reduction filter for platelet can greatly reduce the probability of generating platelet antibody,and postpone the time of producing platelet antibody. Leukocyte reduction filter for platelet deserves to be spread in clinical practice.

Key concepts: Platelet, Apheresis, Medicine, Platelet transfusion, Antibody, Immunology, Internal medicine, Gastroenterology

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical application of leukocyte reduction filter for platelet — Research Paper | ScholarLens